Longitudinal studies in China and Taiwan have shown that positivity for anti-EBNA1 IgA, anti-VCA IgA, and anti-DNase antibodies were associated with a significantly elevated NPC risk (Zeng et al, 1983, 1985; Chien et al, 2001; Ji et al, 2007; Hsu et al, 2009; Ng et al, 2010; Yu et al, 2011). Here, CD79A is linked to nasopharyngeal carcinoma.